Free Trial

Structure Therapeutics (NASDAQ:GPCR) Receives "Market Outperform" Rating from JMP Securities

Structure Therapeutics logo with Medical background

Structure Therapeutics (NASDAQ:GPCR - Get Free Report)'s stock had its "market outperform" rating reissued by equities research analysts at JMP Securities in a research report issued on Monday,Benzinga reports. They presently have a $89.00 target price on the stock. JMP Securities' target price points to a potential upside of 322.20% from the stock's previous close.

A number of other brokerages have also commented on GPCR. William Blair initiated coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an "outperform" rating for the company. Citigroup began coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They set a "buy" rating and a $60.00 target price for the company. Finally, HC Wainwright cut their target price on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Monday, May 12th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $76.17.

View Our Latest Stock Report on GPCR

Structure Therapeutics Stock Down 3.3%

Shares of GPCR stock traded down $0.71 during trading on Monday, reaching $21.08. The company's stock had a trading volume of 550,991 shares, compared to its average volume of 843,884. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -24.23 and a beta of -1.87. The business has a fifty day moving average price of $23.46 and a 200-day moving average price of $24.04. Structure Therapeutics has a one year low of $13.22 and a one year high of $47.48.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Research analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. increased its holdings in Structure Therapeutics by 45.1% in the 4th quarter. Principal Financial Group Inc. now owns 791,134 shares of the company's stock valued at $21,456,000 after acquiring an additional 245,775 shares during the last quarter. Handelsbanken Fonder AB purchased a new stake in Structure Therapeutics in the fourth quarter worth about $4,475,000. Jones Financial Companies Lllp grew its stake in Structure Therapeutics by 29.8% in the fourth quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company's stock valued at $115,000 after purchasing an additional 971 shares during the last quarter. Assetmark Inc. increased its position in Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock valued at $62,000 after buying an additional 953 shares in the last quarter. Finally, M&T Bank Corp increased its holdings in shares of Structure Therapeutics by 100.0% in the fourth quarter. M&T Bank Corp now owns 18,110 shares of the company's stock valued at $492,000 after purchasing an additional 9,055 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

(Get Free Report)

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Featured Stories

Analyst Recommendations for Structure Therapeutics (NASDAQ:GPCR)

Should You Invest $1,000 in Structure Therapeutics Right Now?

Before you consider Structure Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.

While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines